• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
By DAVE BUTLER
Oct 29, 2018 | 06:53 AM EDT
Stocks quotes in this article: GILD, ABBV

If you are buying into Gilead Sciences' (GILD) better-than-expected earnings, be ready to ride the dividend, because you won't see price growth this year. That's my view, at least. -. The company's third quarter results showcase my point. Despite beating analyst's views, revenue and earnings both fell. I don't really care if a company beats estimates if its profits still drop 22%. That's plain bad.

With the market corrections taking place, I don't see Gilead making any runs this year. They have a ton of cash, but haven't put it to use yet. All that said, I think hepatitis sales are so low at this point that revenue should start to stabilize. To that end, Gilead is a cheap stock with a nice dividend.

"Beating" Estimates

As the company's once-coveted hepatitis C drugs continue to decline in sales, profits continue to falter. It's been one of the most straightforward revenue declines I've ever watched. Every quarter, Harvoni is down. Look at the annual financials. Every year, sales and net income dip. This year, as the company works to build new outlets for growth, they've allowed expenses to keep gaining even as sales decline. In the first nine months of the year, costs and expenses have increased 11.4% to $9.27 billion, while revenue fell 18.9% to $16.33 billion. Operating income is down 40% for the year to $7 billion; while third-quarter operating income dropped 31% to $2.62 billion.

Of course, earnings have followed suit. Third-quarter net income fell 22.6% to just under $2.1 billion. On that income, diluted earnings per share decreased a comparable 22.1% to $1.62 per share.

From here in, I do think the effects of further fallout in hepatitis will be less disruptive to the overall revenue stream. The sales figures for the drugs in this lineup have fallen so much that HIV drugs are the main source of cash for the company now. Last year, Hep C treatments garnered the company over $2 billion in sales revenue in the third quarter. In Q3 2018, the lineup brought in a little over $900 million. In contrast, HIV drugs brought in over $3.7 billion in the third quarter. That's an 11.8% increase year over year.

Yes, I believe most of the pain from the decline of a juggernaut (i.e. their hepatitis C lineup) is behind us. Now, the company faces the prospect of finding a second act comparable to the first. We all know about the $12 billion acquisition of Kite Pharma that gained them access to the novel T Cell treatments for cancer. It is cutting edge medicine, but the company hasn't made much progress on revenue in this area, yet. Currently being marketed as Yescarta, for the treatment of lymphoma, this new treatment has a ways to go in terms of negotiating pricing with coverage providers, institutions, etc. Sales for Yescarta were $75 million in the third quarter. No one should ever complain about $75 million, but there's a long way to go here.

Other initiatives include the release of generic versions of Harvoni and Epclusa. Competitors like AbbVie (ABBV) have been lowering the earnings potential of these Hepatitis C drugs as they compete over price (not to mention that a drug that cures, results in a declining consumer base). This might help some, but I don't see it as a key driver of the share price.

Time to Buy?

Gilead will now be relying on HIV sales revenue to keep things flowing while it works to bolster its results in oncology treatments. On top of that, pay close attention to how development proceeds on their pipeline for Rheumatoid Arthritis -- Filgotinib has passed through phase three clinical trials with very positive results. It's worth noting, though, that there are already competitors within the arthritis space. While they most certainly have some positive things happening here, it's not enough to get me enthused on the level that Harvoni or Sovaldi did. Furthermore, the drug isn't finished with all the safety studies. It will not be a contributing factor to sales in the foreseeable future.

So, the only thing that can drive the share price through the fourth quarter and into the first quarter of 2019 will be continued HIV growth, and the eventual hiring of a new CEO. Personally, I think the CEO thing will be a short-lived catalyst in a positive or negative direction. Gilead's stock has demonstrated over and over again that it follows sales and earnings. The low P/E demonstrates that fact. Many want to see the new CEO in order to derive a better understanding of where the company is going. I think it's already abundantly clear that they're moving into oncology. You don't spend $12 billion if that isn't where your priority is.

I've been critical of the stock through recent quarters, as the progressive hepatitis decline has outpaced rising HIV drugs. I think the Hep. C sales have fallen so low that things should start to bottom out in terms of overall revenue declines. Biktarvy, the company's newest in the HIV lineup, has displayed solid sales of $606 million in the first nine months of the year. This should help keep the company's current position relatively stable.

I reiterate, I don't see much momentum right now that will move the stock up. The continued steadiness of HIV should keep the stock where it is, but it won't create bullish trends. We need to see big gains. We need to see that Kite Pharma deal start yielding bigger returns. We need to see management find more places to put that $30 billion cash hoard.

Thanks to its cheap share price, I think Gilead will be relatively insulated from the broader market fallout, but that won't create upside. There are a lot of opportunities here, but they haven't been put to use. Be ready to ride that dividend.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity | Healthcare | Earnings | Drug Approvals | Stocks

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login